I cannot provide a meaningful medical recommendation because your question "In kidney" is incomplete and does not specify what clinical decision needs to be made.
To give you an evidence-based answer, I need you to complete your question.
Here are examples of complete kidney-related questions I could answer:
- "Should I start an SGLT2 inhibitor in a patient with CKD and diabetes?"
- "When should I discontinue an ACE inhibitor in chronic kidney disease?"
- "What is the target blood pressure for a patient with CKD and albuminuria?"
- "Should I screen for CKD in patients with diabetes?"
- "What medications should I start for a patient with CKD stage 3 and proteinuria?"
The evidence provided includes the 2024 KDIGO guidelines 1, which offer comprehensive recommendations for:
- RAS inhibitor use based on albuminuria levels and diabetes status
- SGLT2 inhibitor initiation criteria (eGFR ≥20 ml/min per 1.73 m²)
- Monitoring parameters after medication initiation
- When to continue or discontinue kidney-protective therapies
Please rephrase your question with specific clinical details including:
- The patient scenario (CKD stage, comorbidities, current medications)
- The specific intervention or decision you're considering
- What outcome you're trying to achieve
Once you provide a complete question, I can give you a direct, evidence-based recommendation prioritizing patient morbidity, mortality, and quality of life.